OSIRIS THERAPEUTICS,INC. (OTCMKTS:OSIR) Files An 8-K Changes in Registrant’s Certifying Accountant

OSIRIS THERAPEUTICS,INC. (OTCMKTS:OSIR) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01. Changes in Registrant’s Certifying Accountant.

Story continues below

As previously announced, on December 17, 2015, following the conclusion of a competitive process managed by the Audit Committee of the Board of Directors of Osiris Therapeutics, Inc. (the “Company”), the Company selected Ernst & Young LLP (“Ernst & Young”) to serve as its independent registered public accounting firm for the year ended December 31, 2015. On May 16, 2017, Ernst & Young completed its standard client acceptance procedures and was formally engaged by the Company as its independent registered public accounting firm.

During the years ended December 31, 2016 and December 31, 2015 and through May 16, 2017, neither the Company, nor anyone on its behalf, has consulted Ernst & Young with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report was provided to the Company nor oral advice was provided to the Company that Ernst & Young concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).


About OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR)

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR) Recent Trading Information

OSIRIS THERAPEUTICS, INC. (OTCMKTS:OSIR) closed its last trading session down -0.60 at 5.90 with 2,921,453 shares trading hands.

An ad to help with our costs